Economic Development

Kailos Genetics, a company focused on putting genetics into practice through its proprietary targeted enrichment technology, announced today that it will attend the 30th Annual JP Morgan Healthcare Conference to announce results from its fourth quarter R&D initiatives.
 
Brian Pollock, Kailos Genetics CEO, commented: “While we saw early interest in this proprietary targeted enrichment technology, our goal this quarter as a company was to optimize our platform’s performance – both in terms of the number of unique amplicons that could be tested in a single tube, to reducing workflow time – while maintaining the high specificity seen with this technology. JP Morgan provides us an opportunity to update the many companies that have engaged us in discussions to date.”
To read the rest of the story from Kailos Genetics, click here. 

EGEN, Inc. is collaborating with the National Cancer Institute's Nanotechnology Characterization Laboratory in Frederick, Md., to accelerate human clinical testing of a nanotechnology-based gene therapy for brain cancer.
 
EGEN's candidate gene therapy -- which  relies on nanoparticles for effective delivery to the tumor site -- is already being evaluated in Phase I and II clinical trials in patients with colorectal and ovarian cancers. EGEN is seeking to begin Phase I trials against glioblastoma, a brain cancer that is difficult to treat.
 

Microarrays Inc. (MI) launches its new MI PathArray assays for studying targeted biological pathways. These pathway-centric arrays provide the highest microarray sensitivity in the form of more sharply focused research-specialty arrays, in a multi-assay format. The MI PathArray assays bring a fresh research tool to laboratories involved in the exploration of biological pathways.
 

HudsonAlpha Institute among featured projects

by Ron Nyren
Collaboration is the watchword in contemporary life sciences facilities.  Even as scientists from a variety of disciplines share knowledge in pursuit of new treatments for diseases, municipal governments are pooling resources with the private sector to create biotechnology clusters, universities are teaming with nonprofit companies and nonprofit organizations are working with for-profit companies to speed the "bench to bedside" process -- getting the results of research translated into therapies that start healing people as soon as possible.
Go here for the rest of the article.

Download PDF: 

42_sameer_singhal.pdf

42 Contributing Writer Mike Kelley spoke with Sameer Singhal, a Division Director at CFD Research Corporation in Cummings Research Park. A Huntsville native, he grew up in Jones Valley and met his wife Ruchi, an Atlanta native, at Georgia Tech. Sameer and Ruchi make their home in the Hampton Cove area of Huntsville.